AllDocs -> cancers

Mayo Clin Proc. • August 2005;80(8):1087-1097 • www.mayoclinicproceedings.com 1087 NON-HODGKIN LYMPHOMA : DIAGNOSIS AND TREATMENT SYMPOSIUM ON ONCOLOGY PRACTICE: HEMATOLOGICAL MALIGNANCIES From the Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minn (S.M.A.); and Department of Medical Oncology, University of Nebraska, Omaha (J.A.). Address correspondence to Stephen M. Ansell, MD, PhD, Division of Hema- tology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905 (e-mail: ansell.stephen@mayo.edu). Individual reprints of this article and a bound booklet of the entire Symposium on Oncology Practice: Hema- tological Malignancies will be available for purchase from our Web site www.mayoclinicproceedings.com. © 2005 Mayo Foundation for Medical Education and Research Non-Hodgkin Lymphoma : Diagnosis and Treatment S TEPHEN M. ...

doi:10.1136/jmg.2004.027433 2005;42;595-601 J. Med. Genet. and M A Tucker L R Goldin, M L McMaster, M Ter-Minassian, S Saddlemire, B Harmsen, G Lalonde chromosome 4 lymphoma : evidence for a susceptibility gene on A genome screen of families at high risk for Hodgkin http://jmg.bmjjournals.com/cgi/content/full/42/7/595 Updated information and services can be found at: These include: References http://jmg.bmjjournals.com/cgi/content/full/42/7/595#BIBL This article cites 37 articles, 7 of which can be accessed free at: Rapid responses http://jmg.bmjjournals.com/cgi/eletter-submit/42/7/595 You can respond to this article at: service Email alerting top right corner of the article Receive free email alerts when new articles cite this article - sign up in the box at the Topic collections ...

lymphoma 1581 Zevalin™ (Ibritumomab tiuxetan) For Patients With Follicular NHL Refractory to Rituximab and for Relapsed or Refractory Low-Grade, Follicular or Transformed B-cell NHL Treatment of Indolent NHL No treatment is curative No regimen has been shown to be superior in terms of survival Additional treatment options are needed In the absence of a cure or survival benefit, treatments that induce remission and prolong time off therapy are valuable Monoclonal Antibodies Provide a Targeted Approach to Treatment of NHL Apoptosis Antibody-dependent cell-mediated cytotoxicity (ADCC) Complement-dependent cytolysis (CDC) Radioimmunotherapy with Y-90 Zevalin Ibritumomab Murine monoclonal antibody parent of Rituximab Tiuxetan Conjugated ...

North American Educational Forum on Lymphoma November 2004, San Francisco, CA Hodgkin’s Lymphoma Joseph M. Connors, MD, British Columbia Cancer Agency This is a transcript of an audio recording from the North American Educational Forum on Lymphoma , provided as a free service to the public. A professional medical transcription service produced the transcript. LRF and the speakers have not edited the content for accuracy or omissions of information. Patients are encouraged to talk to their physicians for complete information on how their disease should be diagnosed, treated, and followed. LRF’s educational materials are not intended to take the place of medical care or advice from your doctor. Webcasts (audio and slides) are archived at lymphoma .org. Connors: Joseph M. Connors, MD, University of British Columbia, Vancouver F: Female speaker M: Male speaker Connors: ...

North American Educational Forum on Lymphoma November 2004, San Francisco, CA Follicular Indolent Lymphoma Sandra Horning, M.D, Stanford University Medical Center This is a transcript of an audio recording from the North American Educational Forum on Lymphoma , provided as a free service to the public. A professional medical transcription service produced the transcript. LRF and the speakers have not edited the content for accuracy or omissions of information. Patients are encouraged to talk to their physicians for complete information on how their disease should be diagnosed, treated, and followed. LRF’s educational materials are not intended to take the place of medical care or advice from your doctor. Webcasts (audio and slides) are archived at lymphoma .org. Horning: Sandra Horning, MD F: Female speaker M: Male speaker Horning: Well, I think maybe what ...

North American Educational Forum on Lymphoma November 2004, San Francisco, CA The Healing Companion Caring for Others And Yourself Jeff Kane, MD This is a transcript of an audio recording from the North American Educational Forum on Lymphoma , provided as a free service to the public. A professional medical transcription service produced the transcript. LRF and the speakers have not edited the content for accuracy or omissions of information. Patients are encouraged to talk to their physicians for complete information on how their disease should be diagnosed, treated, and followed. LRF’s educational materials are not intended to take the place of medical care or advice from your doctor. Webcasts (audio and slides) are archived at lymphoma .org. Kane: Jeff Kane, MD, Sierra Nevada Cancer Center F: Female speaker M: Male speaker F: I’d like to introduce Dr. Jeff ...

North American Educational Forum on Lymphoma November 2004, San Francisco, CA Mantle Cell Lymphoma Ralph M. Meyer. M.D., Ph.D., This is a transcript of an audio recording from the North American Educational Forum on Lymphoma , provided as a free service to the public. A professional medical transcription service produced the transcript. LRF and the speakers have not edited the content for accuracy or omissions of information. Patients are encouraged to talk to their physicians for complete information on how their disease should be diagnosed, treated, and followed. LRF’s educational materials are not intended to take the place of medical care or advice from your doctor. Webcasts (audio and slides) are archived at lymphoma .org. Meyer: Ralph M. Meyer, Juravinski Cancer Centre and McMaster University F: Female speaker M: Male speaker Meyer: Good morning. My ...

North American Educational Forum on Lymphoma November 2004, San Francisco, CA Biology and Management of Waldenström’s Macroglobulinemia Steven P. Treon, MD, MA, PhD This is a transcript of an audio recording from the North American Educational Forum on Lymphoma , provided as a free service to the public. A professional medical transcription service produced the transcript. LRF and the speakers have not edited the content for accuracy or omissions of information. Patients are encouraged to talk to their physicians for complete information on how their disease should be diagnosed, treated, and followed. LRF’s educational materials are not intended to take the place of medical care or advice from your doctor. Webcasts (audio and slides) are archived at lymphoma .org. Treon: Steven P. Treon, MD, MA, PhD, Dana Farber Cancer Institute F: Female speaker M: Male speaker ...

March 2005 Total registrations 50787 New registrations 4163 (since EBMT 2004) Total number of centres 538 New centres 16 EBMT Lymphoma Registry Page 2 March 2005 Lymphoma transplants: by year of transplant 0 1000 2000 3000 4000 5000 6000 1 9 7 8 1 9 7 9 1 9 8 0 1 9 8 1 1 9 8 2 1 9 8 3 1 9 8 4 1 9 8 5 1 9 8 6 1 9 8 7 1 9 8 8 1 9 8 9 1 9 9 0 1 9 9 1 1 9 9 2 1 9 9 3 ...

of the file http://www.ebmt.org/4Registry/Registry_docs/slides/slides2005/2005lym.ppt . G o o g l e automatically generates html versions of documents as we crawl the web. To link to or bookmark this page, use the following url: http://www.google.com/search?q=cache:OMahzAggEi0J:www.ebmt.org/4Registry/Registry_docs/slides/slides2005/2005lym.ppt+lymphoma+filetype:pdf+OR+filetype:doc+OR+filetype:ppt+OR+filetype:xls+OR+filetype:rtf&hl=it&ct=clnk&cd=288&lr=lang_en Google is neither affiliated with the authors of this page nor responsible for its content. These search terms have been highlighted: lymphoma 1581 March 2005 Total registrations 50787 New registrations 4163 (since EBMT 2004) Total number of centres 538 ...

Mayo Clin Proc, February 2004, Vol 79 Lymphoma Treatment in Severe Liver Dysfunction 169 Mayo Clin Proc . 2004;79:169-175 169 © 2004 Mayo Foundation for Medical Education and Research Original Articl Original Article Therapeutic Options in Patients With Lymphoma and Severe Liver Dysfunction I RENE M. G HOBRIAL , MD; R OBERT C. W OLF , P HARM D; D ENISE L. P EREIRA , MD; R AFAEL F ONSECA , MD; W ILLIAM L. W HITE , MD; J OSEPH P. C OLGAN , MD; T HOMAS M. H ABERMANN , MD; D AVID J. I NWARDS , MD; S VETOMIR ...

M. Keijzer et al. (Eds.): EuroGP 2004, LNCS 3003, pp. 78–88, 2004. © Springer-Verlag Berlin Heidelberg 2004 Lymphoma Cancer Classification Using Genetic Programming with SNR Features Jin-Hyuk Hong and Sung-Bae Cho Dept. of Computer Science, Yonsei University, 134 Shinchon-dong, Sudaemoon-ku, Seoul 120-749, Korea hjinh@candy.yonsei.ac.kr, sbcho@cs.yonsei.ac.kr Abstract. Lymphoma cancer classification with DNA microarray data is one of important problems in bioinformatics. Many machine learning techniques have been applied to the problem and produced valuable results. However the medical field requires not only a high-accuracy classifier, but also the in-depth analysis and understanding of classification rules obtained. Since gene expression data have thousands of features, it is nearly impossible to represent and understand their complex relationships directly. In this ...

New mouse lymphoma study The study by Utteridge et al published in the September 2002 edition of Radiation Research is a significantly enhanced follow-on study to a 1997 study by Repacholi et al that received widespread media coverage at the time. The Australian National Health & Medical Research Council funded study at Adelaide University tested whether exposure of digital mobile phone emissions increased tumour incidence (lymphomas) in cancer prone mice as well as in normal mice. The study used 1600 mice compared to the 200 mice used in the earlier study. The mice were exposed to radiofrequency levels of 0.25, 1.0, 2.0 and 4.0 W/Kg for an hour per day for 24 months compared to a single dose and 18 month period in the Repacholi study. The Utteridge study reported that they could not reproduce the results of the earlier study which found digital mobile phone emissions doubled the cancer rate ...

305 Volume 18, Number 5 CASE REPORT C A S E R E P O R T Radiation Medicine: Vol. 18 No. 5, 305–310 p.p., 2000 Multifocal Primary Lymphoma of Bone: Scintigraphy and MR Findings before and after Treatment Masako Yuki, Isamu Narabayashi, Kazuhiro Yamamoto, Tadafumi Shimizu, Yasunori Tanaka, Toshiaki Tatsumi, and Tsuyoshi Komori A case of multifocal primary lymphoma of bone is reviewed. Ga-67 citrate, Tc-99m HMDP, and Tl-201 scintigraphs all showed multifocal radiotracer accumulation. CT showed subtle osteolytic and osteosclerotic changes with surrounding soft tissue density mass. MRI clearly showed abnormal signal intensity in the bone marrow. After systemic chemotherapy and infield radiotherapy, the patient showed clinically complete remission. MRI showed reduction of the extraosseous components, but there was little signal change in the bone marrow despite the clinical ...

245 Volume 18, Number 4 ORIGINAL ARTICLE ORIGINAL ARTICLE Radiation Medicine: Vol. 18 No. 4, 245–248 p.p., 2000 Radiotherapy for Localized Relapse in Patients with Non-Hodgkin’s Lymphoma : A Preliminary Report Katsumasa Nakamura,* Naonobu Kunitake,* Masahiko Kimura,* Yoshiyuki Shioyama,* Hiromi Terashima,** and Kouji Masuda* Purpose: To evaluate the usefulness of radiotherapy for relapse of non-Hodgkin’s lymphoma (NHL) at a localized site. Methods: Of 79 patients with relapsed intermediate- or high-grade NHL, 13 patients (16.5%) with a localized relapse were analyzed retrospectively. Results: Five patients were treated with radiotherapy alone and eight were treated with radiotherapy plus conventional chemotherapy (CHOP or other combinations). Radiotherapy was delivered to the involved field to a mean total dose of 34.1 Gy (range, 21-51 Gy). The 5- year overall ...

RYAN’S HOPE TEAM Light The Night Walk for the Leukemia & Lymphoma Society EVENT DATE: Saturday, October 2, 2004 LOCATION: Reston Town Center in Reston, Virginia TIME: 5:00 PM to 9:00 PM (actual walk starts at 6:30 PM) What is Light the Night Walk? The Leukemia & Lymphoma Society organized this walk to help raise funds for curing leukemia, non-Hodgkin’s lymphoma , Hodgkin's lymphoma and myeloma. Proceeds are used to fund research for treatments, cures, government advocacy, patient assistance programs, community outreach, and education programs. To learn more about this event, go to http://www.lightthenight.org/hm_ltn . Why are we doing this? This event is a very personal one for the Fontanilla family because we have close friends whose lives have been impacted by blood cancers. In 2002, Angie’s best friend from high school, Kristina Robinson , lost ...

Patients Against Lymphoma 3774 Buckwampum Road, Riegelsville PA 18077 Tel: 610-346-8419 Fax: 801-409-5736 Email: KarlS@Lymphomation.org STUDY PROPOSAL Combine molecular profiling research with evaluating first-line use of patient-specific idiotype cancer vaccines KEY BENEFITS: Acquire tissue once for multiple and complementary purposes. Avoid ethical issue of acquiring tissue solely for basic research. Quickly accrue patients for important clinical and basic research without precluding optimal benefit from standard treatment in future. BACKGROUND: Patient interest is an important starting point for study design. Patients with untreated stable disease provide an important untapped opportunity to investigate immune therapies, while also increasing our understanding of the molecular biology of the disease – which can provide the context for understanding outcomes, and the variable ...

LYMPHOMA RESEARCH -FOUNDATION July 30, 2004 The Honorable Lester Crawford, D.V.M, Ph.D Acting Commissioner Food and Drug Administration Parklawn Building 5600 Fishers Lane Room 1471 Rockville, MD 20857 RE: Docket No. 2004-N-0181 Dear Dr. Crawford: The Lymphoma Research Foundation (LRF) is the nation’s largest lymphoma -focused voluntary health organization devoted exclusively to funding lymphoma research and providing patients and healthcare professionals with critical information on the disease. We appreciate the opportunity to comment on the report, “Innovation/Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products,” and to offer recommendations to improve the development of new cancer therapies. We appreciate FDA’s effort to identify problems in the development of new therapies and to invite proposals from the public ...

CAD , a c-Myc Target Gene, is Not Deregulated in Burkitt's Lymphoma Cell Lines Susanna M. Mac and Peggy J. Farnham* Department of Oncology, McArdle Laboratory for Cancer Research, University of Wisconsin±Madison, Madison, Wisconsin Although the Myc family of transcription factors is upregulated in many human tumors, it is unclear which genes are targets for the deregulated Myc. Previous studies suggest that hamster and rat carbamoyl phosphate synthase, aspartate transcarbamylase, dihydroorotase Cad genes are regulated by c-Myc. In fact, of all putative target genes thought to be activated by c-Myc, only the Cad gene showed loss of growth regulation in rat cells nullizygous for c-Myc. However, it was unknown whether upregulation of CAD, which performs the first three rate-limiting steps of pyrimidine biosynthesis, contributes to c-Myc's role in human neoplasia. To explore this possibility, we cloned the human ...

J. Neurosurg: Spine / Volume 5 / July, 2006 J Neurosurg Spine 5: 61–64, 2006 61 ODGKIN lymphomas primarily affecting the central nervous system are uncommon. Those causing spinal cord compression have been invariably ex- tradural. On further examinations, most of these reported lesions were found to extend contiguously into the ex- tradural compartment from adjacent sites. To our knowl- edge, we present the first case of a presumed primary in- tradural extraarachnoid Hodgkin lymphoma . Case Report History. In March 2000, this 42-year-old otherwise healthy man underwent examination for a 10-year history of neck pain. Initially, the pain was dull in intensity and not associated with any symptoms in the upper or lower extremities. In September 2000, the neck pain increased dramatically, becoming associated with numbness and tin- gling in the left thumb and index ...

This Report on Leukemia, Lymphoma and Multiple Myeloma Contains: • Incidence and Mortality by Cancer Type • Cancer Trends by Age Group and Gender • Incidence Rates by Race and Gender • Survival Probabilities • Risk Factors • Sources of Data and Additional Information Blood-related Cancers: Incidence and Mortality in Ohio Source: Ohio Cancer Incidence Surveillance System, Ohio Department of Health, 2005. Leukemia, Lymphoma & Multiple Myeloma In Ohio, 1998-2002 August 2005 The estimated completeness of reporting for Hodgkin’s Lymphoma was 100 percent for the five-year time period. However, completeness estimates for Leukemia (86 percent), non- Hodgkin’s Lymphoma (89 percent) and Multiple Myeloma (90 percent) ...

WINTER 2005 | 06 New Lymphoma Treatments are Saving Lives Story on page 2 96264A_d 12/7/05 9:06 AM Page 1 Page 2 RESEARCH 2 Treatment Advances for Lymphoma Have Reduced Deaths by 70% New state-of-the-art treatment advances for patients with follicular lymphoma , previously considered an incurable cancer, have reduced deaths in the first four years by 70 percent. A newly published study recommends that doctors carefully choose their patients’ initial ther- apies because there may be significant differences in overall survival rates, according to researchers at the James P. Wilmot Cancer Center. Scientists compared outcomes for 960 patients treated with three different regimens and survival rates vary from 91 percent for the newest treatments using monoclonal anti- bodies, to 69 ...

975 Risk Factors For Primary Central Nervous System Lymphoma A Case–Control Study BACKGROUND. The incidence of primary central nervous system lymphoma David Schiff, M.D. 1 (PCNSL) has increased over time in both immunocompetent and immunodeficient Vera J. Suman, Ph.D. 2 individuals. The reasons for the increase among immunocompetent patients are Ping Yang, M.B., Ph.D. 2 unclear. Walter A. Rocca, M.D., M.P.H. 1,2 METHODS. The authors conducted a case-control study of PCNSL at the Mayo Brian P. O’Neill, M.D. 1 Clinic based on cases from local community and referral practices. Cases were all PCNSL patients without immunodeficiency diagnosed between 1975 and 1994 (n 1 Department of Neurology, ...

JCPSP 2006, Vol. 16 (4): 307-308 307 I NTRODUCTION Splenomegaly with fever is a common clinical presentation with long list of differential diagnosis. Common causes of splenomegaly in this country 1 are known but rare causes of splenomegaly are often overlooked, as there is reluctance to perform major surgery as a diagnostic procedure. Following report describes a case of primary splenic lymphoma in a patient with massive splenomegaly and fever diagnosed after splenectomy, which proved to be therapeutic as well. C ASE REPORT A 55 years old lady presented with complaints of high fever along with sweats, heaviness in left side of abdomen, aggravated by food intake, and weight loss of four months duration. Patient complained of generalized weakness, malaise and loss of appetite, but gave no history of bleeding from any site or skin rash. ...